Please login to the form below

Not currently logged in
Email:
Password:

Cadence Pharma

This page shows the latest Cadence Pharma news and features for those working in and with pharma, biotech and healthcare.

Mallinckrodt pays $1.2bn for Sucampo Pharma

Mallinckrodt pays $1.2bn for Sucampo Pharma

Mallinckrodt pays $1.2bn for Sucampo Pharma. The Irish group will acquire Amitizia, Rescula and a pipeline of rare disease projects. ... bought Cadence Pharma for $1.3bn, Questcor for $6.5bn, immunotherapy outfit Therakos for $1.3bn and nuclear imaging

Latest news

  • Ireland's Mallinckrodt buys US regenerative medicine firm Ireland's Mallinckrodt buys US regenerative medicine firm

    Ireland's Mallinckrodt Pharma has continued its acquisitive streak with a deal to buy Stratatech, a US firm developing a biologic treatment for severe burns. ... Cadence Pharma and its injectable painkiller Ofirmev (acetaminophen).

  • Mallinckrodt cuts $5.6bn deal to buy Questcor Mallinckrodt cuts $5.6bn deal to buy Questcor

    Mallinckrodt cuts $5.6bn deal to buy Questcor. Irish company continues move from medical imaging to pharma products. ... It is the second transaction for Mallinckrodt in as many months, having announced a $1.3bn bid for Cadence Pharma and its

  • Mallinckrodt offers $1.3bn for Cadence Pharma

    Mallinckrodt offers $1.3bn for Cadence Pharma. Deal would include injectable painkiller Ofirmev. ... Irish pharma company Mallinckrodt has agreed a $1.3bn deal to buy US biotech Cadence Pharmaceuticals and its fast-growing injectable painkiller Ofirmev.

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CACTUS

Founded in 2002, Cactus Communications is a fully integrated, global scholarly communications company with offices in Japan, South Korea, India,...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics